吴娜琼

• 1:中国医学科学院阜外心血管病医院血脂异常与心血管疾病诊治中心

摘要(Abstract)：

<正>在美国,每年约785 000人新发冠心病(CAD),约470 000人再发CAD。2007年美国平均每6个死亡病例中有1例死于CAD。尽管脑卒中发生率下降,但美国2007年的死亡数据显示每18个死亡病例中有1例死于脑卒中。血脂异常是CAD最主要的危险因素,甚至是CAD的首要条件。流行病学资料也显示高胆固醇血症以及冠状动脉粥样硬化是缺血性脑卒中的危险因素[1]。

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 吴娜琼

参考文献(References)：

• [1]Nicholls S,Lundman P.The emerging role of lipopro teins inatherogenesis:beyond LDL cholesterol[J].Semin Vasc Med,2004,4:187-195.
• [2]Summary of the second report of the National CholesterolEducation Program(NCEP)Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults(Adult Treatment PanelⅡ)[J].JAMA,1993,269:3015-3023.
• [3]Yusuf S,Hawken S,Ounpuu S,et al.Effect of potentiallymodifiable risk factors associated with myocardial infarction in52 countries(the INTERHEART study):case-control study[J].Lancet,2004,364(9438):937-952.
• [4]Kastelein JJ,van der Steeg WA,Holme I,et al.Lipids,apolipoproteins,and their ratios in relation to cardiovasculare v e ntswithstatintreatment[J].Circulation,2 0 0 8,117(23):3002-3009.
• [5]Bonaa KH,Njolstad I,Ueland PM,et al.Homocysteinelowering and cardiovascular events after acute myocardialinfarction[J].N Engl J Med,2006,354(15):1578-1588.
• [6]Shepherd J,Blauw GJ,Murphy MB,et al.Pravastatin inelderly individuals at risk of vascular disease(PROSPER):arandomised controlled trial[J].Lancet,2002,360(9346):1623-1630.
• [7]Ridker PM,Morrow DA,Rose LM,et al.Relative efficacy ofatorvastatin 80 mg and pravastatin 40 mg in achieving the dualgoals of low-density lipoprotein cholesterol<70 mg/dl andC-reactive protein<2 mg/L:an analysis of the PROVE-ITTIMI-22 trial[J].J Am Coll Cardiol,2005,45(10):1644-1648.
• [8]Preiss D,Seshasai SR,Welsh P,et al.Risk of Incident Diabeteswith Intensive-Dose Compared with Moderate-Dose StatinTherapy:A Meta-Analysis[J].JAMA,2011,305(24):2556-2564.
• [9]Gagne C,Bays HE,Weiss SR,et al.Ezetimibe StudyGroup.Efficacy and safety of ezetimibe added to ongo ingstatin therapy for treatment of patients with primaryhypercholesterolemia[J].Am J Cardiol,2002,90(10):1084-1091.
• [10]McKenney JM,Farnier M,Lo KW,et al.Safety and efficacyof long-term co-administration of fenofibrate and ezetimibein patients with mixed hyperlipidemia[J].J Am Coll Cardiol,2006,47(8):1584-1587.
• [11]Tenkanen L,M ntt ri M,Kovanen PT,et al.Gemfibrozil inthe treatment of dyslipid emia:an 18-year mortality follow-up of the Helsinki Heart Study[J].Arch Intern Med,2006,166(7):743-748.
• [12]Ginsberg HN,Elam MB,Lovato LC,et al.Effects of combina-tion lipid therapy in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1563-1574.
• [13]AIM-HIGH Investigators.The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovas cular eventsin patients with atherosclerotic cardiovascular disease andoptimally treated low-density lipoprotein cholesterol:baselinecharacteristics of study participants.The AtherothrombosisIntervention in Metabolic syndrome with low HDL/hightriglycerides:impact on Global Health outcomes(AIM-HIGH)trial[J].Am Heart J,2011,161(3):538-543.
• [14]Baigent C,Landray MJ,Reith C,et al;SHARP Investigators.The effects of lowering LDL cholesterol with simvastatin plusezetimibe in patients with chronic kidney disease(Study ofHeart and Renal Protection):a randomised placebo-controlledtrial[J].Lancet,2011,377(9784):2181-2192.
• [15]Barter P,Gotto AM,LaRosa JC,et al.Treating to New TargetsInvestigators.HDL cholesterol,very low levels of LDL choles-terol,and cardiovascular events[J].N Engl J Med,2007,357(13):1301-1310.
• [16]Kinlay S,Schwartz GG,Olsson AG,et al.Myocardial IschemiaReduction with Aggressive Cholesterol Lowering StudyInvestigators.High-dose atorvastatin enhances the declinein inflammatory markers in patients with acute coronarysyndromes in the MIRACL study[J].Circulation,2003,108(13):1560-1566.
• [17]Baigent C,Keech A,Kearney PM,et al.Cholesterol TreatmentTrialists’(CTT)Collaborators.Efficacy and safety of choles-terol-lowering treatment:prospective meta-analysis of datafrom 90,056 participants in 14 randomised trials of statins[J].Lancet,2005,366(9493):1267-1278.